NCT06576180View on ClinicalTrials.gov

Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Cognitive Function in Patients With Resectable Head and Neck Squamous Cell Carcinoma

RecruitingOBSERVATIONAL
Enrollment

306

Participants

Timeline

Start Date

August 23, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Carboplatin（ neoadjuvant）

Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

DRUG

Paclitaxel （neoadjuvant）

Paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

DRUG

Anti-PD-1 Drugs

Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle

PROCEDURE

Surgical resection

Standard of care

Trial Locations (1)

510000

RECRUITING

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guanzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER